drugset / Trial / NCT00493467
Zevalin (Ibritumomab Tiuxetan) for Early Stage Indolent Lymphomas
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find out if giving (Rituxan) rituximab with 90Y (ibritumomab tiuxetan) (90 Y Zevalin®) may be effective in treating low-grade lymphoma. The safety of this combination treatment will also be studied.
Timeline
- Start
- 2006-06
- Primary completion
- 2015-04
- Completion
- 2022-08-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 1.6 mg | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 11.1 mbq/kg | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 14.8 mbq/kg | Intravenous |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 185 mbq | Intravenous |